 RSL3 is a novel compound that induces cell death in non-small cell lung cancer, NSCLC, cells. It does so by activating ferroptosis, which is a type of program cell death caused by oxidative stress. This process involves the accumulation of lipid peroxides, the depletion of glutathione, and the inhibition of glutathione reductase, resulting in the loss of reduced glutathione and the activation of ferritin. Additionally, RSL3 blocks the activity of glutathione peroxides, which further increases the amount of lipid peroxide and leads to cell death.